AzTrials
AzTrials

Postoperative PainNCT06253260

Analgesic Efficacy of Sequential Rapid Versus Slow Intrathecal Injection Of Dexmedetomidine Followed by of Hyperbaric Bupivacaine in Inguinal Hernia Repair Surgery

A study testing Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair and Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery in people with Postoperative Pain, run by Cairo University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Versus Sequential Slow Injection of Both Drugs in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Postoperative Pain
What is being tested?
Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair and Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteEgypt
Study dates
15 Feb 2024to 20 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • patients undergoing inguinal hernia repair surgery.
  • Age between 18 years and 65 years.
  • Both sexes
  • ASA I \& ASA II

Who cannot join

  • Patients refusal
  • Pregnant women
  • Duration of surgery more than 2 hours.
  • Chronic use of opioids or tranquilizers.
  • Incooperative patients e.g mentally retarded.
  • Patients with any contraindications to spinal anesthesia
  • Allergy to the used drugs.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Kasr Alainy hospitals

    Cairo, 11562

Other trials in Egypt

About this study

Official title: Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Versus Sequential Slow Injection of Both Drugs in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery

Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Versus Sequential Slow Injection of Both Drugs in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery

Read the detailed description

Once enrolled in the study, patients will be randomly assigned into two groups; rapid sequential group (Group A: n= 25) and normal sequential group (Group B: n=25). Randomization will be done by computer generated numbers and concealed by serially numbered, opaque and sealed envelopes. Upon arrival to the operating room, Wide bore intravenous line will be inserted, premedications (ondansetron 4 mg and midazolam 0.05 mg/Kg) will be administered, and routine monitors (Electrocardiogram - non-invasive blood pressure monitor - pulse oximeter) will be applied. The patient will be assisted into the sitting position, and sterilized surgical drapes will be placed to their back. Spinal anesthesia will be administered at L4-L5 using a complete aseptic technique. Group (A): will receive spinal anesthesia by applying sequential rapid injection of dexmedetomidine (5 µg in 0.5 ml saline, in insulin syringe within 1 second) followed by slow injection of 17.5 mg (3.5 ml within 12

-15 seconds) of 0.5% of heavy bupivacaine with no time lag between these injections. Group (B): will receive spinal anesthesia by applying normal sequential injection of 0.5 mL of 5 µg dexmedetomidine (injected over 3-4 seconds using a 5 ml syringe and mixed with cerebrospinal fluid (via barbotage), followed by slow injection of 17.5 mg (3.5 ml within 12 -15 seconds) of 0.5% of heavy bupivacaine with no time lag between these injections. Then the patient will be asked to lie down. The sensory level will be assessed by the cold ice technique every minute for 10-minutes. Motor blockade will be assessed every 5 min by the Bromage scale (4). After the T6 level is reached, the surgeon will be asked to operate. In case of failed spinal anesthesia (defined as failure to reach T6 level within 10 mins), the patient will be excluded, and further management will be according to the attending anesthetist. After spinal anaesthesia noninvasive blood pressure will be measured for then every 3 mins for 30 mins then every 5 mins till the end of operation. The occurrence of hypotension (defined as mean blood pressure \<65 mmHg) will be recorded, and an anesthesiologist will be allowed to manage it by giving ephedrine (5-10 mg, intravenous [IV]) and IV fluids. If bradycardia occurred (heart rate\<55 bpm), it will be managed by intravenous 0.5 mg atropine. Postoperative pain management All patients will receive acetaminophen 1gm/6 hours. Visual analogue scale (VAS) will be assessed at 0.5-, 1-, 2-, 4-, 6-, 8-, 10-, 12-,18- and 24-hour post operatively. Rescue analgesia administered in the form of (0.5-1 mg/kg) of intramuscular pethidine will be given on if VAS score was \>3 Measurement tools

Patients will be monitored using:

  • ECG, non-invasive blood pressure monitor, pulse oximeter.
  • VAS (Visual analogue scale) pain assessment.
Being tested
Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair, Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia RepairDrug

    Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery

  • Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair SurgeryDrug

    Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery

Study groups in NCT06253260
Study groupRoleWhat they receive
(Group A): rapid sequential groupActive comparatorNot described
Receives: Drug: Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair
(Group B): normal sequential groupActive comparatorNot described
Receives: Drug: Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Duration of postoperative analgesia

    time from reaching the sensory level of T6 until the need of first dose of rescue analgesia

    Measured: 24 hours

Secondary outcomes (4)
  1. Onset of sensory block

    defined as the time needed to lose cold sensation when using the ice-cold test at the T6 dermatomal level

    Measured: 20 minutes

  2. Onset of motor block using Bromage scale

    defined as the time from giving spinal anesthesia until a modified Bromage score of IV will be reached

    Measured: 30 minutes

  3. VIisual Visual analouge scale Visual analogue scale (VAS) score at 0.5-, 1-, 2-, 4-, 6-, 8-, 10-, 12-, 18-and 24-hour post operatively

    VAS score, a scale from 0 to 10, as 0 means no pain and 10 represents the most severe pain VAS score at 0.5-, 1-, 2-, 4-, 6-, 8-, 10-, 12-, 18-and 24-hour post operatively, a

    Measured: 24 hrs

  4. Total dose of postoperative pethidine

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Feb 2024
  2. Study start15 Feb 2024
  3. Primary completion20 May 2024
  4. Study completion20 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06253260
Sponsor's protocol ID
MD-367-2021
Status last verified
May 2024
First submitted
2 Feb 2024
Last updated
24 May 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair and Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery in people with Postoperative Pain, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Duration of postoperative analgesia (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in